Core Viewpoint - Sichuan University has announced multiple government procurement intentions for laboratory instruments, with a total budget of 88.45 million yuan, covering 32 items of equipment [3][4]. Procurement Overview - The procurement includes various advanced instruments such as X-ray residual stress analyzers, fully automated chemiluminescence immunoassay analyzers, fully automated blood culture systems, and more, with expected procurement time from June 2025 to January 2026 [4][5]. Instrument Details - **X-ray Residual Stress Analyzer**: Utilizes X-ray diffraction principles for non-destructive measurement of residual stress in materials, applicable in aerospace, mechanical manufacturing, and nuclear power [5]. - **Fully Automated Blood Cell Analyzer**: Employs electrical impedance and flow cytometry for rapid blood cell counting and classification, crucial for disease screening and diagnosis [6]. - **Glycated Hemoglobin Analyzer**: Detects glycated hemoglobin levels using high-performance liquid chromatography, essential for diabetes management and monitoring [7]. Detailed Procurement List - The procurement list includes specific instruments with detailed requirements, such as: - **Plant Live Imaging System**: For gene expression analysis and plant growth observation [10]. - **X-ray Residual Stress Analyzer**: For non-destructive testing of various materials [10]. - **Automated Blood Culture System**: Capable of processing at least 120 bottles simultaneously [12]. - **High-throughput Automated Thermoluminescence Measurement System**: Designed for high-capacity automated measurements [15]. Budget and Timeline - The total budget for the procurement is 88.45 million yuan, with specific timelines for delivery and installation ranging from 40 days to 180 days post-contract signing [4][10][12].

Core Viewpoint - The article highlights the significant growth potential of Mindray Medical's animal healthcare segment, driven by increasing pet ownership and spending, as well as the company's strategic investments and product development in this area [5][8][10]. Group 1: Company Developments - Mindray Medical is planning a secondary IPO in Hong Kong, aiming to raise at least $1 billion (approximately 7.8 billion HKD) [3]. - The company has established a global headquarters for animal healthcare in Longhua, Shenzhen, with a total investment of 1.774 billion RMB, expected to generate an annual output value exceeding 12 billion RMB [2][7]. - The company reported a projected revenue of 36.726 billion RMB and a net profit of 11.668 billion RMB for 2024, positioning it as one of the largest mainland companies seeking a secondary listing in Hong Kong [5]. Group 2: Market Potential - The animal healthcare market is experiencing rapid growth, with the Chinese pet economy projected to reach 592.8 billion RMB in 2023, growing at a rate of 20.1%, and expected to reach 1.15 trillion RMB by 2028 [10]. - The increase in pet ownership is attributed to demographic changes such as aging populations, declining birth rates, and a rise in single-person households [5][10]. Group 3: Product Development and Strategy - Mindray Medical has leveraged its expertise in human medical devices to accelerate the development of animal healthcare products, resulting in a product range that includes imaging, diagnostics, and life support systems for pets [7][8]. - The company has launched several new animal-specific medical devices, including anesthesia machines and diagnostic analyzers, with international animal healthcare business growth exceeding 30% in the first three quarters of 2024 [7][8]. - The international market now accounts for nearly 80% of the company's animal healthcare revenue, indicating strong demand and growth potential [8].